34th week of 2012 patent applcation highlights part 43 |
Patent application number | Title | Published |
20120214688 | Methods for Diagnosing Breast, Colon, Lung, Pancreatic and Prostate Cancer Using miR-21 and miR-17-5p - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 2012-08-23 |
20120214689 | Methods for Diagnosing Breast and Lung Cancer Using miR-210 and miR-213 - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 2012-08-23 |
20120214690 | Methods for Diagnosing Colon, Stomach, Prostate and Pancreas Cancer Using miR-223 - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 2012-08-23 |
20120214691 | Methods for Diagnosing Breast Cancer Using miR-21, miR-125-1, miR-125b-2 and miR-145 - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 2012-08-23 |
20120214692 | Methods for Diagnosing Pancreatic Cancer Using miR-103-1, miR-103-2, miR-24-2 and miR-107 - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 2012-08-23 |
20120214693 | Methods for Diagnosing Breast Cancer Using MicroRNAs - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 2012-08-23 |
20120214694 | Methods for Diagnosing Colon Cancer Using MicroRNAs - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 2012-08-23 |
20120214695 | Methods for Diagnosing Lung Cancer Using MicroRNAs - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 2012-08-23 |
20120214696 | Methods for Diagnosing Pancreatic Cancer Using MicroRNAs - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 2012-08-23 |
20120214697 | Methods for Diagnosing Prostate Cancer Using MicroRNAs - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 2012-08-23 |
20120214698 | Methods for Diagnosing Stomach Cancer Using MicroRNAs - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 2012-08-23 |
20120214699 | Methods for Diagnosing Breast Cancer Using MicroRNA Signatures - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 2012-08-23 |
20120214700 | Methods for Diagnosing Colon Cancer Using MicroRNA Signatures - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 2012-08-23 |
20120214701 | Methods for Diagnosing Lung Cancer Using MicroRNA Signatures - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 2012-08-23 |
20120214702 | Methods for Diagnosing Prostate Cancer Using MicroRNA Signatures - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 2012-08-23 |
20120214703 | Methods for Diagnosing Stomach Cancer Using MicroRNA Signatures - The present invention provides novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis. | 2012-08-23 |
20120214704 | Methods for Identifying DNA Copy Number Changes - Methods of identifying allele-specific changes in genomic DNA copy number are disclosed. Methods for identifying homozygous deletions and genetic amplifications are disclosed. An array of probes designed to detect presence or absence of a plurality of different sequences is also disclosed. The probes are designed to hybridize to sequences that are predicted to be present in a reduced complexity sample. The methods may be used to detect copy number changes in cancerous tissue compared to normal tissue. The methods may be used to diagnose cancer and other diseases associated with chromosomal anomalies. | 2012-08-23 |
20120214705 | BETA-DEFENSIN 2 GENETIC VARIATION PREDICTS H. PYLORI SUSCEPTIBILITY - The present invention relates to correlating high gene copy number and/or the overexpression of β-defensin 2 (“BD2”) with susceptibility to disease conditions resulting from, associated with or mediated by | 2012-08-23 |
20120214706 | RAPID DETECTION OF SNP CLUSTERS - The present invention relates to the rapid detection of clusters of single nucleotide polymorphisms (SNPs) using an array technology. It further relates to the use of these clusters as markers in strain improvement and breeding, and in strain identification. | 2012-08-23 |
20120214707 | METHOD FOR DETECTION OF AN ANALYTE IN A FLUID SAMPLE - A method for detecting an analyte in a fluid sample is disclosed. The method comprises: a) providing a measurement region and a reference region, the measurement region being provided with a receptor for binding the analyte; b) providing at least one light beam so as to travel along the measurement region and along the reference region; c) providing the fluid sample into at least the measurement region; d) detecting by means of a detector an optical pattern provided by the at least one light beam after having travelled along the measurement region and the reference region; and e) deriving a presence of the analyte in the fluid sample from the detected optical pattern, wherein prior to c) a blocking fluid is provided along the measurement region and along the reference region. | 2012-08-23 |
20120214708 | Device and Process for Measuring Cell Properties - The invention relates to a measuring device for measuring at least one property of cells or vesicles, characterized in that is divided into two chambers by a hydrophobic partition having a horizontal opening, these chambers containing electrolyte solution and said opening being closed by a lipid double layer. The invention is characterized in that at least one cell or vesicle contacts the lipid double layer. The invention also relates to methods involving the use of the measuring device and to arrays, measuring chambers and microtitration plates all suited therefor. | 2012-08-23 |
20120214709 | ISOLATING BIOLOGICAL MODULATORS FROM BIODIVERSE GENE FRAGMENT LIBRARIES - The present invention provides a method for identifying a modulator or mediator of a biological activity, which activity includes antigenicity and or immunogenicity, said method comprising the step of:
| 2012-08-23 |
20120214710 | METHOD OF PREDICTING RESPONSE TO THALIDOMIDE IN MULTIPLE MYELOMA PATIENTS - A method of predicting response to thalidomide, or thalidomide analogs, in an individual with cancer, especially cancers for which thalidomide has been implicated as a treatment, such as Multiple Myeloma (MM) employs one or more of a panel of biomarkers that have been shown to be differentially expressed in cancer patients that respond to thalidomide (hereafter “Responders”) relative to cancer patients that do not respond to thalidomide (hereafter “Non-responders). The method involves assaying a biological sample from the individual to determine the abundance of at least three biomarkers including Vitamin-D binding protein precursor (VDB) (Sequence ID 1) and Serum amyloid A protein (SAA) (Sequence ID 3), and at least one of beta-2-microglobulin (B2M) (Sequence ID 4), Haptoglobin (Hp) precursor (fragment) (Sequence ID 5), and zinc-alpha-2-glycoprotein (ZAG) (Sequence ID 2). Correlation of the abundance value for the at least three biomarkers with a reference abundance value from a Responder or Non-responder enables predication of response to thalidomide for the patient. | 2012-08-23 |
20120214711 | AUTOMATED MACHINE FOR TRANSFERRING SOLUTION FROM A SOURCE MICROWELL PLATE TO A DESTINATION MICROWELL PLATE - An automated machine for transferring solution from a source microwell plate to a destination microwell plate. A plurality of pins is used for transferring the solution. The pins are attached to pin assemblies. The pin assemblies are attached to the circumference of a circular dial that is rotatably connected to the automated machine. The circular dial rotates the pins form a solution removal position to a solution transfer position and then to a pin cleaning position. Solution is removed from individual wells at the solution removal position and the solution is transferred to individual wells at the solution transfer position. The pins are cleaned at the pin cleaning position. A computer is programmed to control the automated machine and the transfer of solution. In a preferred embodiment, the computer is programmed to: 1) execute a saved transfer list, 2) accept a customized input list from an operator, 3) execute the customized input list, and 4) save the customized input list for later execution. In a preferred embodiment, the automated machine is utilized for transferring variable volumes of solution from the source microwell plate to the destination microwell plate. | 2012-08-23 |
20120214712 | Methods of Using Polysaccharide Based Cement Additives - A method of servicing a wellbore comprising introducing to the wellbore a wellbore servicing fluid comprising an additive composition comprising a polysaccharide having carboxylate and sulfonate groups. A method of servicing a wellbore comprising preparing at the well site an additive composition comprising a polysaccharide having carboxylate and sulfonate groups, introducing the additive composition into a wellbore servicing fluid, and placing the wellbore servicing fluid into a subterranean formation. A method of preparing a wellbore servicing fluid comprising contacting a polysaccharide composition with an oxidizing agent to form an oxidized polysaccharide, and contacting the oxidized polysaccharide with a sulfonating agent to form a carboxylated sulfonated polysaccharide, and contacting the carboxylated sulfonated polysaccharide with a wellbore servicing fluid. | 2012-08-23 |
20120214713 | Method for Adjusting and Controlling Microbial Enhanced Oil Recovery - The invention discloses a method for adjusting and controlling microbial enhanced oil recovery, which comprises the following steps: (1) analyzing the microbial community structure in produced fluid of an oil reservoir via molecular biological method and/or detecting the metabolites in the produced fluid; (2) adjusting the microorganism(s) to be injected into the oil reservoir and/or the nutrient system corresponding to the microorganism(s); (3) injecting the adjusted microorganism(s) and/or the nutrient system corresponding to the microorganism(s) into the oil reservoir through a water injection well; and (4) obtaining the crude oil from a corresponding beneficial oil producing well. Compared with the prior art, the method of the present invention adjusts microbial community structure in the oil reservoir to evolve toward the direction of facilitating oil production, and the performance of the functional microorganism(s) can be completely realized; the nutrient system is pertinently injected to avoid the blindness of using the nutrient system. Therefore, the method is scientific, economical and effective for the microbial enhanced oil recovery. | 2012-08-23 |
20120214714 | PROCESS FOR ACHIEVING IMPROVED FRICTION REDUCTION IN HYDRAULIC FRACTURING AND COILED TUBING APPLICATIONS IN HIGH SALINITY CONDITIONS - A process for achieving enhanced levels of friction reduction in high salinity conditions, particularly suited to slick-water hydraulic fracturing and coiled tubing applications, uses low charge and preferably uncharged water soluble high molecular weight polymers. A fracturing fluid is injected into a conduit. The fracturing fluid is an aqueous solution comprising at least one water soluble (co)polymer comprising less than 10 mol % ionic monomer(s), and the aqueous solution comprises total dissolved salts concentration ranging from 100,000 mg/L to up to the salt concentration at which the aqueous solution becomes saturated in salts. | 2012-08-23 |
20120214715 | Degradable Perforation Balls and Associated Methods of Use in Subterranean Applications - Methods of making a degradable ball composition comprising a carboxylic acid, a fatty alcohol, a fatty acid salt, a fatty ester, or a combination thereof comprising the steps of: forming a thermoplastic mass, and allowing the thermoplastic mass to cool as to form a degradable ball that is introduced in subterranean treatments by a carrier fluid. | 2012-08-23 |
20120214716 | Alkali Metal Borate and Lubricating Compositions Thereof - The present invention relates to a lubricating composition containing an alkali metal borate. The invention further provides for a method of lubricating a device with grease or a metalworking fluid by employing the lubricating composition containing the alkali metal borate. | 2012-08-23 |
20120214717 | NANOPARTICLE ADDITIVES AND LUBRICANT FORMULATIONS CONTAINING THE NANOPARTICLE ADDITIVES - A method for making a self-dispersing cerium oxide nanoparticles additive for lubricants, a lubricant composition containing the nanoparticles and a method for reducing boundary friction using the nanoparticles. The nanoparticles are made by an improved process of reacting a mixture of organo-cerium salt, fatty acid, and amine in the substantial absence of water and organic solvent at a temperature ranging from about 150° to about 250° C., the improvement comprising reacting the organo-cerium salt, fatty acid and amine in a molar ratio ranging from about 1:1:1 to about 1:2:2 in the reaction mixture to provide the reaction product comprising from about 20 to about 40% by weight of the nanoparticles in a substantially organic medium. | 2012-08-23 |
20120214718 | Antiwear Composition and Method of Lubricating Driveline Device - The present invention relates to a method for lubricating a driveline device comprising supplying to the driveline device a lubricating composition comprising an oil of lubricating viscosity and an antiwear package wherein the antiwear package comprises (a) a derivative of a hydroxycarboxylic acid, and (b) a phosphorus compound selected from the group consisting of an amine salt of a phosphate hydrocarbon ester, a phosphite having at least one hydrocarbyl group with 4 or more carbon atoms, and mixtures thereof. | 2012-08-23 |
20120214719 | LUBRICATING COMPOSITION - The present invention provides a lubricating composition at least comprising: a base oil; and a detergent; wherein the detergent comprises at least 30 mol %, based on the total amount of detergent, of a sulphonate detergent having a B1SI (Base Number) of from 0.1 to 80 mg KOH/ g; wherein the detergent comprises from 30 to 70 mol %, based on the total amount of detergent, of a phenate detergent; wherein the lubricating composition comprises at least 4 wt. % of detergent, based on the total weight of the composition; and wherein the lubricating composition has a TBN (total base number) (according to ASTM D 2896) of at least 10 mg KOH/g. | 2012-08-23 |
20120214720 | Chemical Composition of Matter for the Liquefaction and Dissolution of Asphaltene and Paraffin Sludges into Petroleum Crude Oils and Refined Products at Ambient Temperatures and Method of Use - A chemical composition of matter comprising a wax plasticizing agent (plasticizer) tributoxyethyl phosphate, a mixture of selected long chain fatty acids (preferably C | 2012-08-23 |
20120214721 | GREASE COMPOSITION COMPRISING POLYMER ALLOY, A STRUCTURE PART ENCLOSING THE SAME AND A METHOD FOR PRODUCING THE GREASE COMPOSITION - A grease composition having a thickener, a base oil containing a hydrocarbon oil, and a polymer alloy of an olefin copolymer and a styrene-based copolymer is disclosed. | 2012-08-23 |
20120214722 | TREATMENT SOLUTION FOR PREVENTING PATTERN COLLAPSE IN METAL FINE STRUCTURE BODY, AND PROCESS FOR PRODUCTION OF METAL FINE STRUCTURE BODY USING SAME - There are provided a processing liquid for suppressing pattern collapse of a fine metal structure, containing at least one member selected from the group consisting of an ammonium halide having a fluoroalkyl group, a betaine compound having a fluoroalkyl group, and an amine oxide compound having a fluoroalkyl group, and a method for producing a fine metal structure using the same. | 2012-08-23 |
20120214723 | MACHINE CLEANING METHOD - An automatic dishwashing method or automatic textile washing method uses a cleaning-agent including: a) a liquid cleaning-agent preparation A including at least one bleach activator as well as at least one builder; and b) a liquid cleaning-agent preparation D including at least one oxygen bleaching agent. The cleaning-agent preparations A and D are dispensed into the interior of the machine from a cartridge located in the interior of the machine. Sub-quantities a and d of the cleaning-agent preparations A and D are respectively dispensed into the interior of the machine, residual quantity of the cleaning-agent preparations A and D remaining in the cartridge until the end of the washing method, the residual quantities corresponding to at least twice the sub-quantities a and d, respectively. | 2012-08-23 |
20120214724 | Mixtures OF C10-C13 Alkylphenyl Sulfonates - The invention is directed to mixtures comprising C | 2012-08-23 |
20120214725 | PROCESS TO PRODUCE STABLE SUSPENDING SYSTEM - A process that degasses a structured surfactant composition that comprises at least one surfactant, water, and at least one suspending agent chosen from polysaccharides, gums, and celluloses. By degassing the composition, the suspending agent can form a structured system. Gas, such as air bubbles, disrupts the formation of the structuring system, which reduces the ability of the composition to suspend materials. | 2012-08-23 |
20120214726 | MULTI-PURPOSE CLEANER - A multi-purpose cleaning compound comprising about 4.50% to about 16.50% by volume isopropyl alcohol; about 4.50% to about 16.50% by volume vinegar; about 2.00% and about 8.50% by volume ammonia; about 2.00% by volume of at least one pre-selected surfactant; between about 0.009% and about 0.05% by volume rosemary oil; and about 56.50% and about 86.90% by volume water. | 2012-08-23 |
20120214727 | Granule With Hydrated Barrier Material - A granule having high stability and low dust is described. The granule includes a hydrated barrier material having moderate or high water activity. Also described are methods of producing the granules. | 2012-08-23 |
20120214728 | EX VIVO AND IN VIVO METHODS AND RELATED COMPOSITIONS FOR REGENERATING HEMATOPOIETIC STEM CELL POPULATIONS - Various embodiments provide methods and related compositions for increasing the population size of hematopoietic stem cells (HSCs) in patients that may benefit from reconstitution of stem cells and/or differentiated cells of the blood lineage. The present methods enable the production of HSCs ex vivo and in vivo by reducing latexin expression and/or latexin activity within HSC exposed to various antagonists. Inhibition of latexin expression and/or latexin activity by various antagonists can promote HSC proliferation and/or inhibit HSC apoptosis. Antagonists that can reduce latexin expression and/or latexin activity can be utilized to regenerate endogenous HSCs within patients affected with disorders, diseases, cancers, or therapies for such conditions, that result in the depletion or reduction in HSCs. | 2012-08-23 |
20120214729 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATION - The present invention relates to a composition containing Substance P for preventing or treating an inflammation. The composition containing Substance P according to the present invention exhibits the effect of decreasing leukocytes, neutrophils and hematopoietic stem cells in a blood, which are associated with the inflammation, and of increasing anti-inflammatory cytokines, regulatory T-lymphocytes, anti-inflammatory macrophages and the like, thereby terminating inflammatory response at an early stage, and is thus highly effective in preventing and treating the inflammation caused by a non-traumatic, traumatic, infectious or ischemic retinal injury. | 2012-08-23 |
20120214730 | METHOD OF USING HEPARIN BINDING MOTIF FOR TREATING ASTHMA - The present invention is for an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 9 and using the peptide for treating asthma by reducing cytotoxicity of eosinophil derived toxins in bronchial epithelial cells of the subject suffers from asthma. The method comprises preparing a pharmaceutical composition having the peptide of SEQ ID NO: 9 and administering an effective amount of the composition to the subject. | 2012-08-23 |
20120214731 | COMPOUND WS 727713 - The present invention relates to a new compound useful as a modulator of melanocortin receptors. In particular, the present invention relates to a compound WS727713, a process for production of the compound by culturing, in a culture medium, a WS727713-producing strain belonging to | 2012-08-23 |
20120214732 | Inhibitors of the Trypsin-Like Site of the Proteasome and Methods of Use Thereof - The present invention is an inhibitor of the trypsin-like β2/β2i sites of the proteasome. The inhibitor is characterized as being a peptide-based epoxyketone or vinyl sulfone that contains an arginine or 4-aminomethylene-L-phenylalanine at the C-terminus (i.e., at the P1 position). Methods for using the inhibitor to inhibit the activity of the β2/β2i site of a proteasome and treat a proteasome-mediated disease or condition are also described. | 2012-08-23 |
20120214733 | OXYTOCIN RECEPTOR AGONISTS - The present invention relates to oxytocin receptor agonist compounds, pharmaceutical compositions comprising the same, use of such compounds for the manufacture of a medicament for treatment of inter alia, abdominal pain, irritable bowel syndrome (IBS), autism, erectile dysfunction, female sexual dysfunction, labor induction and maintenance, lactation induction and maintenance, postpartum hemorrhage, Post Traumatic Stress Disorder (PTSD), pain, anxiety and other conditions, as well as to methods for the treatment of such conditions, wherein such compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification: | 2012-08-23 |
20120214734 | TREATMENT OF METABOLIC DISORDERS - The present invention provides methods for treating, preventing, and/or delaying the onset of metabolic disorders including multi-factorial syndromes such as insulin-insensitivity and metabolic syndrome by administering an effective amount of an ACE inhibitor. | 2012-08-23 |
20120214735 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS - Acetamide derivatives, their stereoisomers, tautomers, prodrugs, pharmaceutically acceptable salts, polymorphs, solvates and formulations thereof for the prophylaxis, management, treatment, control of progression, or adjunct treatment of diseases and/or medical conditions where the activation of glucokinase would be beneficial, are disclosed. | 2012-08-23 |
20120214736 | COMPOSITIONS AND METHODS FOR THE MODULATION OF JNK PROTEINS - The invention provides compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a gene encoding a Jun N-terminal kinase 1 (JNK1 protein. | 2012-08-23 |
20120214737 | METHODS FOR PROTECTING DOPAMINERGIC NEURONS FROM STRESS AND PROMOTING PROLIFERATION AND DIFFERENTIATION OF OLIGODENDROCYTE PROGENITORS BY NRG-2 - The invention features methods of treatment and diagnosis using NRG-2 polypeptides, nucleic acid molecules, and antibodies. The invention also provides novel NRG-2 polypeptides and nucleic acid molecules. | 2012-08-23 |
20120214738 | THERAPEUTIC AGENT AND THERAPEUTIC METHOD FOR PERIODONTAL DISEASES AND PULPAL DISEASES - The objects of the present invention are: to provide a therapeutic agent and a therapeutic method for periodontal diseases and pulpal diseases, a transplant for periodontal tissue regeneration, and a method for regenerating the periodontal tissue. | 2012-08-23 |
20120214739 | FGF VARIANTS AND METHODS FOR USE THEREOF - The present invention provides fibroblast growth factor variants demonstrating enhanced receptor subtype specificity and/or affinity. Preferred embodiments include both variants having enhanced activity that act as improved agonists and variants having reduced activity that act as antagonists. Methods of utilizing preferred FGF variants in preparation of medicaments for the treatment of skeletal disorders including skeletal dysplasia, osteoporosis and enhancing bone fracture healing and cartilage healing processes are provided. | 2012-08-23 |
20120214740 | Medicinal Compositions Containing Highly Functionalized Chimeric Protein - There is provided an FGF2 substitute-containing medicinal composition which comprises, as an active ingredient, a chimeric protein comprising the amino acid sequence of an FGF1 protein in which a partial sequence including a sequence of at least positions 62-83 within a sequence of positions 41-83 is substituted with a partial sequence at the corresponding positions in the amino acid sequence of an FGF2 protein; and the remaining region is formed of the amino acid sequence of FGF1. In particular, this medicinal composition is used for wound healing and for the prevention and treatment of radiation-induced damage, and it exhibits a pharmacological action superior to that of an FGF2 medicinal composition, and further, it can be easily formulated into a preparation. | 2012-08-23 |
20120214741 | VDAC1 COMPOSITIONS AND METHODS OF USE THEREOF FOR REGULATING APOPTOSIS - The present invention relates generally to the mitochondrial protein, voltage-dependent anion channel (VDAC), polynucleotides encoding same and variants thereof, as well as peptide fragments, peptide derivatives and analogs. In particular, the present invention is directed to VDAC1 and specific amino acid and polynucleotide sequences thereof useful in inducing or regulating apoptosis and to pharmaceutical compositions comprising same useful in the treatment of diseases associated with aberrant apoptosis. | 2012-08-23 |
20120214742 | GABA RELEASE-REGULATING AGENT IN CEREBELLUM - A GABA (gamma-aminobutyric acid) release-inhibiting agent in the cerebellum and a composition for treating pathological symptoms caused by over-release of GABA in the cerebellum, each comprising a Bestrophin 1(Best1) channel inhibitor as an active ingredient; a GABA release-promoting agent in the cerebellum and a composition for treating pathological symptoms caused by the deficit of GABA in the cerebellum, each comprising a Best1 channel activator as an active ingredient; and a method for screening a GABA release-regulating agent in the cerebellum, which uses Best1 channel as target, are provided. | 2012-08-23 |
20120214743 | ITCH SUPPRESSANT - The present invention provides an itch suppressant containing cholecystokinin 2 receptor agonist such as a peptide having an amino acid sequence homologous with a partial amino acid sequence of at least seven C-terminal amino acids of the peptide having the amino acid sequence represented by SEQ:ID No. 1 as an active ingredient as a rapid-acting itch suppressant effective in treating skin illnesses associated with strong itch such as atopic dermatitis having few side effects. | 2012-08-23 |
20120214744 | POLYPEPTIDES AND NUCLEIC ACIDS FOR TREATING ERBB2-DEPENDENT CANCERS - The present invention relates to polypeptides, nucleic acids and pharmaceutical compositions suitable for use in the treatment of ErbB2 dependent-cancers, in particular of tumors overexpressing ErbB2 or expressing mutated forms of the ErbB2 gene. | 2012-08-23 |
20120214745 | Deuterated Cyclosporine Analogs and Methods of Making the Same - Cyclosporine derivatives are disclosed which possess enhanced efficacy and reduced toxicity over naturally occurring and other presently known cyclosporin and cyclosporine derivatives. The cyclosporine derivatives of the present invention are produced by chemical and isotopic substitution of the cyclosporine A (CsA) molecule by: (1) Chemical substitution and optionally deuterium substitution of amino acid 1; and (2) deuterium substitution at key sites of metabolism of the cyclosporine A molecule such as amino acids 1, 4, 9. Also disclosed are methods of producing the cyclosporine derivatives and method of producing immunosuppression with reduced toxicity with the disclosed cyclosporine derivatives. | 2012-08-23 |
20120214746 | USE OF A COMPOSITION COMPRISING A NON-FERMENTED RICE PEPTIDE HYDROLYZATE FOR STIMULATING HAIR GROWTH - The present invention relates to the use of a composition comprising at least one non-fermented rice peptidic hydrolyzate as an active agent for slowing down and limiting hair loss and/or stimulating hair growth. Said composition is also intended to protect the follicular adult stem cells as well as their specific microenvironment. In addition, the composition according to the invention combats the aging and particularly the photoaging of hair. Lastly, the present invention relates to several non-therapeutic treatment methods utilizing said composition. | 2012-08-23 |
20120214747 | RECOMBINANT HUMAN ALPHA1- ANTITRYPSIN - The present invention relates recombinant human α1-antitrypsin (rhAAT) comprising N-linked glycans, wherein at least 10% of said N-linked glycans are tetra-antennary glycans; and the degree of capping with sialic acid on said N-linked glycans (Z/A) is at least 50%. The invention further relates to rhAAT for use as a medicament, in particular for use in the prevention and/or treatment of a disease associated with AAT deficiency, and/or a disease involving neutrophil-mediated tissue damage. | 2012-08-23 |
20120214748 | NOVEL PEPTIDES, PROCESS FOR PREPARATION THEREOF, AND USE THEREOF - The invention relates to peptides of the general formula (I) GX | 2012-08-23 |
20120214749 | MICROPARTICLES COMPRISING SOMATOSTATIN ANALOGUES - Disclosed are microparticles comprising a somatostatin analogue embedded in a biocompatible pharmacologically acceptable polymer matrix for a long acting release and pharmaceutical compositions comprising such microparticles. | 2012-08-23 |
20120214750 | CRYSTALLINE FORM OF LINACLOTIDE - The present invention relates to crystalline forms of linaclotide, as well as to various methods and processes for the preparation and use of the crystalline forms. | 2012-08-23 |
20120214751 | Glucosyl Stevia Composition | 2012-08-23 |
20120214752 | Glucosyl Stevia Composition | 2012-08-23 |
20120214753 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION - The present invention provides a solid pharmaceutical composition comprising a cocrystal of (1S)-1,5-anhydro-1-[3-(1-benzothien-2-ylmethyl)-4-fluorophenyl]-D-glucitol and L-proline, in combination with crystalline cellulose, and also provides a method for producing the composition. | 2012-08-23 |
20120214754 | FGF RECEPTOR-ACTIVATING N-ACYL OCTASACCHARIDES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF - The invention relates to FGF receptor-activating N-acyl octasaccharides having Formula (I), wherein: R | 2012-08-23 |
20120214755 | METHODS OF PRODUCING AND USING NUTRITIONAL AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE ONE OR MORE ACTIVE SUBSTANCES - Methods for producing a composition that includes an active agent, nutraceutical and pharmaceuticals compositions, and methods for ameliorating and/or treating a disease using the composition that includes an active substance are described herein. More particularly, methods for producing a composition that contains one or more active substances such as oleocanthal, pharmaceutical compositions that include one or more active substances such as oleocanthal, and methods of ameliorating and/or treating inflammation using compositions that contains one or more active substances such as oleocanthal are described. | 2012-08-23 |
20120214756 | COOPERATIVE CONVEYANCE OF BASIC ACTIVE PRINCIPLES BY AMPHIPHILIC ACID MOLECULES - The present invention relates to an intermolecular association complex of an amphiphilic carrier and an active principle G, having the following general formula (I), as well as to the compositions containing same, to the uses thereof, particularly as a drug, and to the method for preparing same. | 2012-08-23 |
20120214757 | Methods and Compositions for Treating Cancer Using Proteasome Inhibitors - The present invention relates to therapeutic compositions for treating cancer or preventing the growth of cancer cells, e.g., tumor growth, in a subject. The present invention also relates to methods for treating cancer, e.g., inhibiting tumor growth, in a subject who has become resistant to treatment, by administering to a subject an effective amount of a proteasome inhibitor and an effective amount of a therapeutic agent, e.g., a chemotherapeutic agent. The present invention further relates to methods for purging bone marrow, i.e., removing cancer cells from bone marrow, by exposing the bone marrow cells to a proteasome inhibitor and a therapeutic agent, e.g., a chemotherapeutic agent. | 2012-08-23 |
20120214758 | TYROSINE KINASE RECEPTOR ANTAGONISTS AND METHODS OF TREATMENT FOR PANCREATIC CANCER - A method of treatment is disclosed whereby cancer cells are brought into contact with a formulation comprising an inhibitor of tyrosine kinase receptors. The formulation may be comprised of an injectable carrier and two or more tyrosine kinase receptor inhibitors which may be nordihydrogluaiaretic acid (NDGA) and doxyrubicine. | 2012-08-23 |
20120214759 | TREATMENT OF KLEBSIELLA PNEUMONIAE INFECTIONS WITH ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS - A method for treating a | 2012-08-23 |
20120214761 | PRE-MIXED, READY-TO-USE IV BOLUS NICARDIPINE COMPOSITIONS AND METHODS OF USE - Provided herein are ready-to-use premixed bolus injection pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions. | 2012-08-23 |
20120214762 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR - The invention relates to novel compounds of Formula I: | 2012-08-23 |
20120214763 | MEMORY FIXATION ACCELERATOR - A medicament for promoting memory consolidation, which comprises, as an active ingredient, a non-natural retinoid, preferably a retinoid having a basic skeleton comprising an aromatic ring bound with an aromatic carboxylic acid or tropolone by means of a bridging group, more preferably 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid or 4-[(3,5-bis-trimethylsilylphenyl)-carboxamido]benzoic acid. | 2012-08-23 |
20120214764 | METHOD AND KIT FOR GASTRO-INTESTINAL CLEANSING - A method of cleansing a mammalian GI tract is described and includes ingestion of polyethylene glycol (PEG) and magnesium citrate in a split-dose regimen. The split-dose regimen provides effective cleansing of the GI tract while minimizing discomfort and side effects to the patient A kit packaged with a first and second portion of PEG, and a first and second portion of magnesium citrate, and optionally simethicone is also provided. | 2012-08-23 |
20120214765 | BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS - Compounds and methods of treating anti-inflammatory conditions are disclosed. | 2012-08-23 |
20120214766 | CANNABINOID RECEPTOR MODULATORS - The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB1 receptor and the CB2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pain, for example bone and joint pain, muscle pain, dental pain, migraine and other headache pain, inflammatory pain, neuropathic pain, pain that occurs as an adverse effect of therapeutics and pain associated with osteoarthritis; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; CNS inflammation; atherosclerosis; undesired immune cell activity and inflammation; age-related macular degeneration; cough; leukemia; lymphoma; CNS tumors; prostate cancer; Alzheimer's disease; stroke-induced damage; dementia; amyotrophic lateral sclerosis, and Parkinson's disease. | 2012-08-23 |
20120214767 | TRICYCLIC HETEROCYCLIC COMPOUNDS - Disclosed are compounds of Formula (I) | 2012-08-23 |
20120214768 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF - The invention relates to pyrido[2,3-b]pyrazine compounds of general formulae (Ia) and (Ib), to their preparation and use, for example, for the treatment of malignant disorders and other disorders based on pathological cell proliferations. | 2012-08-23 |
20120214769 | Novel Antagonists of the Glucagon Receptor - The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same. | 2012-08-23 |
20120214770 | SUBSTITUTED BENZOFURANS, BENZOTHIOPHENES, BENZOSELENOPHENES AND INDOLES AND THEIR USE AS TUBULIN POLYMERISATION INHIBITORS - The present invention relates generally to substituted benzofurans, benzothiophenes, and indoles and their use as tubulin polymerisation inhibitors. | 2012-08-23 |
20120214771 | COMPOSITIONS FOR TREATMENT OF CARDIOMETABOLIC DISORDERS - The present invention provides for methods of preventing or improving cardiometabolic disorders/metabolic disorders, compositions and pharmaceutical compositions comprising therapeutically effective amount of therapeutic phospholipid compositions and therapeutically effective amount of one or more lipid modifying agents, including statins. | 2012-08-23 |
20120214772 | COMPOSITIONS FOR TREATMENT OF INFLAMMATORY DISEASES - Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases. | 2012-08-23 |
20120214773 | FORMULATION FOR LIPOPHILIC AGENTS - The invention relates to pharmaceutical formulations of lipophilic therapeutic agents in which such agents are solubilized in largely aqueous vehicles, and processes for preparing and using the same. | 2012-08-23 |
20120214774 | TREATMENT OF SOLID TUMORS WITH RAPAMYCIN DERIVATIVES - Rapamycin derivatives have interesting effects in the treatment of solid tumours, optionally in combination with a chemotherapeutic agent. | 2012-08-23 |
20120214775 | Pharmaceutical Salts of 3-O-(3',3'-Dimethylsuccinyl) Betulinic Acid - Salts of 3-O-(3′,3′-dimethylsuccinyl)Betulinic acid (DSB) are disclosed. Particularly, the preparation, pharmaceutical evaluation, and in vivo bioavailability evaluation of N-methyl-D-glucamine and alkali metal salt forms of DSB are disclosed. Pharmaceutical compositions including these salt forms are used in methods of treating HIV and related diseases. Methods of making the salts of DSB and the pharmaceutical compositions are also provided. | 2012-08-23 |
20120214776 | TOPICAL FORMULATIONS COMPRISING A STEROID - The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders. | 2012-08-23 |
20120214777 | STABILIZED COMPOSITIONS CONTAINING ALKALINE LABILE DRUGS - A stabilized bioadhesive composition containing an alkaline labile drug and a method for its preparation are provided. In one aspect, the composition is a hot-melt extruded (HME) composition comprising a preformed excipient mixture comprising an acidic component and an alkaline thermoplastic matrix-forming material, e.g. polymer. The excipient mixture is formed before blending with an alkaline labile drug. The blend is then hot-melt extruded to form the HME composition. By so doing, the acidic component is able to neutralize or render moderately acidic the excipient mixture. This particular process has been shown to substantially reduce the degradation of an alkaline labile drug during hot-melt extrusion. The excipient mixture softens or melts during hot-melt extrusion. It can dissolve or not dissolve drug-containing particles during extrusion. Various functional excipients can be included in the carrier system to improve process performance and/or improve the chemical or physical properties of the HME composition. | 2012-08-23 |
20120214778 | FULVESTRANT IN A DOSAGE OF 500mg FOR THE TREATMENT OF ADVANCED BREAST CANCER - The present disclosure is directed to fulvestrant at a dosage of 500 mg and its use in the treatment of a postmenopausal woman with advanced breast cancer. | 2012-08-23 |
20120214779 | APPLICATION OF 20(S)-PROTOPANAXADIOL IN PREPARATION OF ANTIDEPRESSANTS - The invention provides the novel use of 20(S)-protopanaxadiol in the preparation of medicaments for the treatment of depressive psychiatric disorders. The pharmacological test results indicated that the compound could remarkably increase the level of NE, 5-HT and HAV in the brains of model rats having depressive disorders, remarkably enhance tremors induced by 5-hydroxytryptophan (5-HTP) and behavioral effects induced by levodopa, and inhibit the re-uptake of 5-HT and NA. | 2012-08-23 |
20120214780 | SUBSTITUTED PORPHYRINS - The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods. | 2012-08-23 |
20120214781 | Antibacterial Food Composition - The present invention relates to an antibacterial food composition comprising a | 2012-08-23 |
20120214782 | New compounds, pharmaceutical compositions and uses thereof - The invention relates to new compounds of the formula I | 2012-08-23 |
20120214783 | VIRAL POLYMERASE INHIBITORS - Compounds of formula I: | 2012-08-23 |
20120214784 | SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS - An ORL-1 receptor antagonist of the formula: its uses, and methods for its preparation are described. ORL-1 antagonists are deemed to be useful in the treatment of depression and/or the treatment of overweight, obesity, and/or weight maintenance post treatment for overweight or obesity. Certain compounds have also demonstrated through animal models that the compounds of the present invention are useful for the treatment of migraines. | 2012-08-23 |
20120214785 | New compounds, pharmaceutical compositions and uses thereof - The invention relates to new compounds of the formula I | 2012-08-23 |
20120214786 | NEW COMPOUNDS - This invention relates to compounds of formula I | 2012-08-23 |
20120214787 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION - The present invention relates to compounds of formula (I): | 2012-08-23 |
20120214788 | HETEROARYL-SUBSTITUTED PIPERIDINES - The invention relates to novel heteroaryl-substituted piperidines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of cardiovascular diseases and tumour diseases. | 2012-08-23 |